StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Total HIV Franchise Product Sales by Quarter

Total HIV Franchise Product Sales — Rest of World sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Total HIV Franchise Product Sales: $393M in Q2 2026, up 6.8% from a year earlier.

Latest, Q2 2026
393
Period ended Jun 30, 2026
Change on a year earlier
+6.8%
368 in Q2 2025
History
37 quarters
Since Q2 2017
Sources
31
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedTotal HIV Franchise Product Sales — Rest of World sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026393+6.8%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026419+13.2%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 2025332+4.7%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025386+12.9%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 2025368+4.2%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 2025370+8.2%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024317+21.5%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024342+0.3%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 2024353+8.3%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024342+14.8%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 2023261-10.6%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 2023341+19.6%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 2023326+15.6%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023298+1.0%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022292+15.9%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 20222850.0%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Total HIV Franchise Product Sales ($M), quarterly Q2 2017–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/hiv-total-row

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.